Canada markets open in 1 hour 17 minutes
  • S&P/TSX

    20,628.92
    -129.42 (-0.62%)
     
  • S&P 500

    4,111.08
    -25.40 (-0.61%)
     
  • DOW

    33,891.02
    -34.99 (-0.10%)
     
  • CAD/USD

    0.7445
    +0.0008 (+0.11%)
     
  • CRUDE OIL

    75.16
    +1.05 (+1.42%)
     
  • BTC-CAD

    30,905.26
    -26.21 (-0.08%)
     
  • CMC Crypto 200

    528.99
    +3.85 (+0.73%)
     
  • GOLD FUTURES

    1,881.40
    +1.90 (+0.10%)
     
  • RUSSELL 2000

    1,957.72
    -27.82 (-1.40%)
     
  • 10-Yr Bond

    3.6340
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,552.25
    +36.75 (+0.29%)
     
  • VOLATILITY

    19.47
    +1.14 (+6.22%)
     
  • FTSE

    7,878.12
    +41.41 (+0.53%)
     
  • NIKKEI 225

    27,685.47
    -8.18 (-0.03%)
     
  • CAD/EUR

    0.6955
    +0.0024 (+0.35%)
     

The Founder of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Joseph Payne, Just Bought A Few More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Founder, Joseph Payne, recently bought US$83k worth of stock, for US$16.51 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

View our latest analysis for Arcturus Therapeutics Holdings

The Last 12 Months Of Insider Transactions At Arcturus Therapeutics Holdings

In fact, the recent purchase by Joseph Payne was the biggest purchase of Arcturus Therapeutics Holdings shares made by an insider individual in the last twelve months, according to our records. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$18.44. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Arcturus Therapeutics Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that Arcturus Therapeutics Holdings insiders own 9.3% of the company, worth about US$46m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Arcturus Therapeutics Holdings Tell Us?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Arcturus Therapeutics Holdings insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Arcturus Therapeutics Holdings. Case in point: We've spotted 1 warning sign for Arcturus Therapeutics Holdings you should be aware of.

Of course Arcturus Therapeutics Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here